Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | DD72H | — |
a patient received an extra MemB (Bexsero); This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 18-year-old female patient who received Men B NVS (Bexsero) (batch number DD72H, expiry date 20-NOV-2027) for prophylaxis. Previously administered products included Bexsero (received 1st dose of Bexsero vaccine on 15-MAR-2023) and Bexsero (received 2nd dose of Bexsero vaccine on 18-APR-2023). On 08-JAN-2025, the patient received the 3rd dose of Bexsero. On 08-JAN-2025, an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: a patient received an extra MemB (Bexsero)). The outcome of the extra dose administered was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-JAN-2025 The reporter reported that a patient received an extra dose of Bexsero vaccine, which led to extra dose administered. The Vaccine Administration Facility is the same as Primary Reporter. The 1st dose was received on 15-Mar-2023, 2nd dose was received on 18-Apr-2023 and 3rd dose was received on 08-Jan-2025.